Payment overview · 2025
General Payments
$233.25
12 reported records · 6 companies
Healthcare provider profile · identity verified
Casey Dillon, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CROSSVILLE, TN · NPI 1184175739
Verified facts
What the public records show
CMS Open Payments records show Casey Dillon, PA received $233.25 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.19 | 33.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.56 | 23.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.54 | 16.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.74 | 10.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.95 | 8.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.27 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.25 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.19 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.55 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 70 |
| Lisinopril | Lisinopril | 237 | 71 |
| Losartan Potassium | Losartan Potassium | 221 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 176 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 51 |
| Omeprazole | Omeprazole | 159 | 41 |
| Metformin Hcl | Metformin Hcl | 141 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 35 |
| Gabapentin | Gabapentin | 136 | 31 |
| Prednisone | Prednisone | 135 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 36 |
| Azithromycin | Azithromycin | 105 | 81 |
| Furosemide | Furosemide | 105 | 30 |
| Montelukast Sodium | Montelukast Sodium | 105 | 32 |
| Simvastatin | Simvastatin | 105 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 32 |
| Famotidine | Famotidine | 88 | 22 |
| Ozempic | Semaglutide | 85 | 17 |
| Alprazolam | Alprazolam | 84 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 58 |
| Eliquis | Apixaban | 79 | 21 |
| Carvedilol | Carvedilol | 77 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 19 |
| Glimepiride | Glimepiride | 76 | 22 |
| Mounjaro | Tirzepatide | 76 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Meloxicam | Meloxicam | 69 | 24 |
| Ketoconazole | Ketoconazole | 67 | 38 |
| Metformin Hcl Er | Metformin Hcl | 67 | 18 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Atenolol | Atenolol | 57 | 16 |
| Fluconazole | Fluconazole | 57 | 38 |
| Dexamethasone | Dexamethasone | 56 | 45 |
| Potassium Chloride | Potassium Chloride | 52 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 17 |
| Ezetimibe | Ezetimibe | 48 | 15 |
| Jardiance | Empagliflozin | 48 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 16 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 29 |
| Cephalexin | Cephalexin | 42 | 36 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 12 |
| Amoxicillin | Amoxicillin | 33 | 25 |
| Ondansetron Odt | Ondansetron | 33 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Armour Thyroid | Thyroid,pork | 29 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Fluorouracil | Fluorouracil | 25 | 23 |
| Methylprednisolone | Methylprednisolone | 25 | 25 |
| Mupirocin | Mupirocin | 25 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233.25 · 12 records | Lilly USA, LLC | Auvelity, MOUNJARO, Natroba, Ozempic, Rybelsus, Spinosad, VOQUEZNA, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error